JP2012510798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510798A5 JP2012510798A5 JP2011538811A JP2011538811A JP2012510798A5 JP 2012510798 A5 JP2012510798 A5 JP 2012510798A5 JP 2011538811 A JP2011538811 A JP 2011538811A JP 2011538811 A JP2011538811 A JP 2011538811A JP 2012510798 A5 JP2012510798 A5 JP 2012510798A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- compound
- seq
- angiopep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 201000010099 disease Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 9
- 206010012601 Diabetes mellitus Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 206010001897 Alzheimer's disease Diseases 0.000 claims 3
- 108010064942 Angiopep-2 Proteins 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 206010058108 Dyslipidaemia Diseases 0.000 claims 3
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 3
- 206010061536 Parkinson's disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 201000010874 syndrome Diseases 0.000 claims 3
- 208000005881 Bovine Spongiform Encephalopathy Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 2
- 208000008466 Metabolic Disease Diseases 0.000 claims 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims 2
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 claims 2
- 201000011452 adrenoleukodystrophy Diseases 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 230000004766 neurogenesis Effects 0.000 claims 2
- 230000000926 neurological Effects 0.000 claims 2
- 230000002980 postoperative Effects 0.000 claims 2
- 150000003141 primary amines Chemical class 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 230000002485 urinary Effects 0.000 claims 2
- 201000001042 variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 102100004948 ABCD1 Human genes 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 102100007495 AR Human genes 0.000 claims 1
- 101700046185 AR Proteins 0.000 claims 1
- 101700019344 ASPA Proteins 0.000 claims 1
- 102100001910 ASPA Human genes 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 201000000013 Alexander disease Diseases 0.000 claims 1
- 206010061888 Amaurotic familial idiocy Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 210000004227 Basal Ganglia Anatomy 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010067608 Canavan disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000004981 Coronary Disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000000538 Diabetic Cardiomyopathy Diseases 0.000 claims 1
- 206010012647 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 208000008279 Dumping Syndrome Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims 1
- 206010057649 Endometrial sarcoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 230000036826 Excretion Effects 0.000 claims 1
- 101700030975 GALC Proteins 0.000 claims 1
- 102100017667 GALC Human genes 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 229940043650 HYPOTHALAMIC HORMONES Drugs 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 claims 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 claims 1
- 208000004356 Hysteria Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 201000008166 Kennedy's disease Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 201000011451 Krabbe disease Diseases 0.000 claims 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010049694 Left ventricular dysfunction Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025169 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010024579 Lysosomal storage disease Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 208000001089 Multiple System Atrophy Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 108009000551 Nephrotic syndrome Proteins 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010052057 Neuroborreliosis Diseases 0.000 claims 1
- 208000001265 Neuroepithelial Neoplasms Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 206010071323 Neuropsychiatric syndrome Diseases 0.000 claims 1
- 208000002040 Neurosyphilis Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 229960002748 Norepinephrine Drugs 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 102100004920 PEX7 Human genes 0.000 claims 1
- 108060006186 PHYH Proteins 0.000 claims 1
- 102100010367 PLP1 Human genes 0.000 claims 1
- 101700047327 PLP1 Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 201000009582 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000011585 Pick's disease Diseases 0.000 claims 1
- 102000006877 Pituitary Hormones Human genes 0.000 claims 1
- 108010047386 Pituitary Hormones Proteins 0.000 claims 1
- 230000036823 Plasma Levels Effects 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036256 Post gastric surgery syndrome Diseases 0.000 claims 1
- 208000003055 Prion Disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 208000005333 Pulmonary Edema Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002025 Tabes Dorsalis Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000009056 Telangiectasis Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 210000002700 Urine Anatomy 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000001925 catabolic Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001886 ciliary Effects 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 201000002574 conversion disease Diseases 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 201000008286 diarrhea Diseases 0.000 claims 1
- 230000001079 digestive Effects 0.000 claims 1
- 230000002183 duodenal Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000000960 hypophysis hormone Substances 0.000 claims 1
- 239000000601 hypothalamic hormone Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000297 inotrophic Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 201000009457 movement disease Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 201000010133 oligodendroglioma Diseases 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 235000020825 overweight Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000001219 parotid gland cancer Diseases 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 238000009101 premedication Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 201000008933 retinal cancer Diseases 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 231100001005 telangiectasia Toxicity 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20094708P | 2008-12-05 | 2008-12-05 | |
| US61/200,947 | 2008-12-05 | ||
| PCT/CA2009/001781 WO2010063124A1 (en) | 2008-12-05 | 2009-12-07 | Peptide therapeutic conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012510798A JP2012510798A (ja) | 2012-05-17 |
| JP2012510798A5 true JP2012510798A5 (US07119074-20061010-C00048.png) | 2013-01-31 |
Family
ID=42232848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538811A Pending JP2012510798A (ja) | 2008-12-05 | 2009-12-07 | ペプチド治療剤コンジュゲートおよびその使用 |
Country Status (11)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1583562T3 (da) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
| ES2383901T5 (es) | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
| ES2424242T3 (es) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| MX2011006685A (es) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos. |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| IN2012DN00248A (US07119074-20061010-C00048.png) * | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
| WO2011070573A1 (en) * | 2009-12-07 | 2011-06-16 | Ben-Gurion University Of The Negev Research And Development Authority | Antimicrobial water treatment membranes and production thereof |
| SG181527A1 (en) | 2009-12-11 | 2012-07-30 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
| EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| EP2694083A2 (en) * | 2011-04-01 | 2014-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
| JP6144673B2 (ja) | 2011-06-03 | 2017-06-07 | オフィディオン インコーポレイティド | 血液脳関門を通過して輸送するための組成物及び方法 |
| WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
| CU24076B1 (es) * | 2011-09-30 | 2015-01-29 | Ct De Ingeniería Genética Y Biotecnología | Composición para el control de patógenos |
| CA2857548A1 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
| AU2012344702A1 (en) * | 2011-12-01 | 2014-06-19 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
| DK2802598T3 (en) * | 2012-01-12 | 2018-03-12 | Univ Ulster | PEPTIDES AND PEPTID DERIVATIVES BASED ON XENIN |
| CN108465112B (zh) * | 2012-05-15 | 2022-04-29 | 西雅图基因公司 | 自稳定接头偶联物 |
| WO2013185235A1 (en) * | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduronidase compounds |
| EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF |
| PT2885010T (pt) | 2012-08-16 | 2020-03-11 | Ipierian Inc | Métodos de tratamento de uma tauopatia |
| AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
| EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
| CA2907454C (en) | 2013-03-21 | 2021-05-04 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| JP6446443B2 (ja) | 2013-06-10 | 2018-12-26 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| EP3074420A2 (en) | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
| US9957311B2 (en) | 2013-12-20 | 2018-05-01 | Tikomed Ab | Surface-binding peptide |
| US20170253643A1 (en) * | 2014-09-02 | 2017-09-07 | Tokyo University Of Science Foundation | Centrally-Acting Peptide Derivative, and Pharmaceutical Composition |
| ES2748117T3 (es) * | 2015-04-22 | 2020-03-13 | Euroimmun Medizinische Labordiagnostika Ag | Diagnóstico de una nueva enfermedad autoinmune |
| US20160346382A1 (en) * | 2015-05-27 | 2016-12-01 | Northwestern University | Carbohydrate-modified particles and particulate formulations for modulating an immune response |
| ES2826827T3 (es) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Métodos para el tratamiento de carcinomatosis leptomeníngea |
| WO2017027848A1 (en) * | 2015-08-12 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier |
| CN106466475B (zh) * | 2015-08-21 | 2021-06-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 抗菌肽与聚合物结合而成的复合物、其制备方法及用途 |
| US11259554B2 (en) | 2015-12-16 | 2022-03-01 | Diet4Life Aps | Dietary peptides |
| US11530243B2 (en) * | 2016-02-18 | 2022-12-20 | Veiove Animal Health Inc. | Non-cleavable substance P conjugates and methods of use thereof |
| US10973812B2 (en) | 2016-03-03 | 2021-04-13 | Regents Of The University Of Minnesota | Ataxia therapeutic compositions and methods |
| BR112018070357A2 (pt) | 2016-04-04 | 2019-01-29 | Bioverativ Usa Inc | anticorpos anticomplemento contra o fator bb e seus usos |
| MX2018012716A (es) | 2016-04-19 | 2019-02-11 | Griffon Pharmaceuticals Inc | Peptidos bioactivos pegilados y usos de los mismos. |
| CN105801709B (zh) * | 2016-04-29 | 2019-10-08 | 北京纽莱福生物科技有限公司 | CBLB502-Fc融合蛋白及其制备方法 |
| BR112019001945A2 (pt) | 2016-08-09 | 2019-05-07 | Seattle Genetics, Inc. | composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto |
| JP2020501611A (ja) * | 2016-12-19 | 2020-01-23 | ハンミ ファーマシューティカル カンパニー リミテッド | 脳標的持続性タンパク質結合体 |
| EP3651807B1 (en) * | 2017-07-13 | 2023-11-01 | City of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
| FR3070264A1 (fr) * | 2017-08-24 | 2019-03-01 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2019043382A1 (en) * | 2017-08-31 | 2019-03-07 | University Of Dundee | DERIVED LEPTIN PEPTIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| CN107964047B (zh) * | 2017-12-18 | 2018-11-02 | 哈尔滨工业大学 | 基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用 |
| CN110337302B (zh) * | 2018-01-15 | 2023-07-21 | 深圳市星银医药有限公司 | 一种马栗树提取物和利那洛肽组合物 |
| WO2019149782A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| CN108490178B (zh) * | 2018-02-13 | 2019-08-30 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于npc诊断及预后预测的标志物及其应用 |
| CA3099434C (en) | 2018-05-04 | 2023-09-05 | Twinpig Biolab Inc. | Targeting m2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide |
| EP3843768A4 (en) | 2018-05-15 | 2022-11-23 | Tran, Lloyd Hung Loi | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING MILD COGNITIVE DISORDER, DEPRESSION AND PSYCHOLOGICAL DISORDERS |
| CN114829383A (zh) * | 2019-06-06 | 2022-07-29 | 阿罗阿生物外科有限公司 | 生物活性剂及其相关方法 |
| CA3144279A1 (en) | 2019-06-26 | 2020-12-30 | Michael E. Selsted | Novel theta defensin analogs |
| CN112279921A (zh) * | 2019-07-11 | 2021-01-29 | 厦门大学 | 用于胞内递送分子的复合物 |
| CN110420317B (zh) * | 2019-07-25 | 2022-11-22 | 中国人民解放军军事科学院军事医学研究院 | Cblb502蛋白在防治创伤后应激障碍中的应用 |
| CN110437308B (zh) * | 2019-08-20 | 2023-05-05 | 倪京满 | 一类对铜绿假单胞菌具有特异活性的含β氨基酸的抗菌肽类似物及其应用 |
| CN110563802B (zh) * | 2019-09-04 | 2023-04-07 | 倪京满 | 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用 |
| CN111808168A (zh) * | 2020-07-21 | 2020-10-23 | 南京农业大学 | 一类褐飞虱硫激肽类似物的合成及应用 |
| CN111704651B (zh) * | 2020-07-27 | 2021-10-08 | 南京安吉生物科技有限公司 | 具有抗衰老作用的多肽rv3和rv4及其应用 |
| CN114057831B (zh) * | 2020-08-07 | 2024-03-12 | 三凡生技研发股份有限公司 | 促进血管增生的短链胜肽及其促进糖尿病伤口愈合的用途 |
| WO2022114906A1 (ko) * | 2020-11-30 | 2022-06-02 | 세종대학교 산학협력단 | 신규 퇴행성 신경질환 치료용 약학적 조성물 |
| CN112656953A (zh) * | 2020-12-30 | 2021-04-16 | 重庆医科大学 | 凝血酶响应型双靶向脂质体及其制备方法和应用 |
| CN112851789B (zh) * | 2021-02-04 | 2022-10-18 | 大理大学 | 一种脑靶向hiv进入抑制剂多肽及其应用 |
| CN113651874B (zh) * | 2021-08-02 | 2023-02-10 | 上海大学 | 一种具有抑制念珠菌生长繁殖作用的订书肽及其制备方法和应用 |
| CN114250204B (zh) * | 2021-12-29 | 2024-02-09 | 深圳瑞德林生物技术有限公司 | 一种羧酸还原酶突变体及酶法合成脱羧肌肽的方法 |
| CN117186239A (zh) * | 2022-01-30 | 2023-12-08 | 南京瑞初医药有限公司 | 融合蛋白及其应用 |
| WO2023224927A2 (en) * | 2022-05-16 | 2023-11-23 | The Children's Medical Center Corporation | Compositions and methods for treating a cardiac disease |
| CN115806740B (zh) * | 2022-11-17 | 2024-01-30 | 四川大学 | 一种集成多模态响应的导电水凝胶及其制备方法和用途 |
| CN116036234B (zh) * | 2023-01-17 | 2024-02-06 | 青岛市中心医院 | 一种用于治疗骨质疏松的药剂 |
| CN116333041A (zh) * | 2023-04-10 | 2023-06-27 | 湖南中晟全肽生化有限公司 | 一种激活grp受体的多肽化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040052814A1 (en) * | 1998-09-28 | 2004-03-18 | Wenyuan Shi | Fusion proteins for targeted delivery of antimicrobial peptides |
| US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| ES2383901T5 (es) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
| CN101511868B (zh) * | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| PL2164866T3 (pl) * | 2007-05-29 | 2014-10-31 | Angiochem Inc | Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek |
-
2009
- 2009-12-07 CN CN200980156247XA patent/CN102348723A/zh active Pending
- 2009-12-07 BR BRPI0923283A patent/BRPI0923283A2/pt not_active IP Right Cessation
- 2009-12-07 AU AU2009322045A patent/AU2009322045A1/en not_active Abandoned
- 2009-12-07 EP EP09829936.5A patent/EP2794663A1/en not_active Withdrawn
- 2009-12-07 CA CA2745499A patent/CA2745499A1/en not_active Abandoned
- 2009-12-07 US US13/133,002 patent/US20110288011A1/en not_active Abandoned
- 2009-12-07 MX MX2011005964A patent/MX2011005964A/es unknown
- 2009-12-07 JP JP2011538811A patent/JP2012510798A/ja active Pending
- 2009-12-07 RU RU2011125366/10A patent/RU2011125366A/ru not_active Application Discontinuation
- 2009-12-07 WO PCT/CA2009/001781 patent/WO2010063124A1/en active Application Filing
- 2009-12-07 CN CN201310616186.9A patent/CN103665170A/zh active Pending
-
2011
- 2011-06-17 ZA ZA2011/04497A patent/ZA201104497B/en unknown
-
2015
- 2015-04-24 US US14/696,193 patent/US20160263235A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510798A5 (US07119074-20061010-C00048.png) | ||
| RU2011125366A (ru) | Конъюгаты терапевтических пептидов и их применение | |
| JP2012505637A5 (US07119074-20061010-C00048.png) | ||
| RU2012103240A (ru) | Мультимерные пептидные конъюгаты и их применение | |
| RU2011118056A (ru) | Конъюгаты агонистов glp-1 и их применение | |
| JP7386218B2 (ja) | グルカゴン及びｇｌｐ－１共アゴニスト化合物 | |
| CN110088125B (zh) | 酰化的glp-1/glp-2双重激动剂 | |
| JP2012531467A5 (US07119074-20061010-C00048.png) | ||
| JP6373270B2 (ja) | 二重ｇｌｐ１／グルカゴンアゴニストとしてのエキセンディン−４誘導体 | |
| EP2057188B1 (en) | Dpp-iv resistant gip hybrid polypeptides with selectable properties | |
| RU2559320C2 (ru) | Новые аналоги глюкагона | |
| US20090203581A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| US20100016237A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| US20100056433A1 (en) | Novel Peptides for Use in the Treatment of Obesity | |
| JP2013534812A5 (US07119074-20061010-C00048.png) | ||
| US20100016238A1 (en) | Peptides for Use in the Treatment of Obesity | |
| US7811989B2 (en) | Peptide YY analogs | |
| JP2015502918A5 (US07119074-20061010-C00048.png) | ||
| MX2008002028A (es) | Polipeptidos hibridos con propiedades de seleccion. | |
| KR102505628B1 (ko) | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 | |
| JP2012510803A5 (US07119074-20061010-C00048.png) | ||
| US20230071371A1 (en) | Peptide conjugates and methods of use | |
| WO2017160669A1 (en) | Insulin-incretin conjugates | |
| JP2010516654A (ja) | 肥満の治療に使用される新規ペプチド | |
| WO2022247701A1 (zh) | 多激动剂及其应用 |
